Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients

BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghemo, Alessio, Rumi, Maria Grazia, Monico, Sara, Banderali, Matteo, Russo, Antonio, Ottaviani, Francesco, Vigano, Mauro, D’Ambrosio, Roberta, Colombo, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2011
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/
https://www.ncbi.nlm.nih.gov/pubmed/22308157
http://dx.doi.org/10.5812/kowsar.1735143X.733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/
https://www.ncbi.nlm.nih.gov/pubmed/22308157
http://dx.doi.org/10.5812/kowsar.1735143X.733

Ejemplares similares